Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Titan Pharma (TTNP) Announces Pricing of $2.2 Million Registered Direct Offering of Common Stock, Warrants
-
Titan Pharmaceuticals Announces Pricing of $2.2 Million Registered Direct Offering
-
Capstone Turbine (CPST) PT Raised to $4 at Maxim Group, Following Announcement of Completing UK Remanufacturing Facility Upgrades
-
Maxim Group Downgrades Habit Restaurants (HABT) to Hold, Following Acquisition
-
SINTX TECHNOLOGIES INFORMS STOCKHOLDERS OF KEY DATES AND TERMS RELATED TO ANNOUNCED RIGHTS OFFERING
-
SINTX TECHNOLOGIES INFORMS STOCKHOLDERS OF KEY DATES AND TERMS RELATED TO ANNOUNCED RIGHTS OFFERING
-
Maxim Group Upgrades Atossa Genetics (ATOS) to Buy
-
ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock
-
Castor Maritime Inc. Reports Financial Results for the Three and Nine Months Ended September 30, 2019
-
SCYNEXIS Announces Closing of $35 Million Public Offering of Common Stock and Warrants
-
Biocept Announces Closing of $10.0 Million Underwritten Public Offering
-
ContraFect (CFRX) Prices Approximately $10 Million Public Offering of Common Stock and Concurrent $3 Million Private Placement of Common Stock to Pfizer
-
ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock and Concurrent $3 Million Private Placement of Common Stock to Pfizer
-
ContraFect (CFRX) Announces Proposed Common Share Offering & Concurrent Private Placement of Common Share to Pfizer Inc. (PFE)
-
ContraFect Corporation Announces Proposed Public Offering of Common Stock and Concurrent Private Placement of Common Stock to Pfizer Inc.
-
Customers Bancorp Announces Closing of $74,750,000 Subordinated Notes Offering Including Full Exercise of Overallotment Option
-
Biocept (BIOC) Announces Pricing of $10 Million Underwritten Public Offering of Common Stock, Warrants
-
Biocept Announces Pricing of $10.0 Million Underwritten Public Offering
-
Maxim Group Starts Soliton (SOLY) at Buy
-
Customers Bancorp Announces Pricing of $65 Million Subordinated Notes Offering Rated “BBB-” by Kroll Bond Rating Agency*
-
Customers Bancorp Commences Public Offering of Subordinated Notes Rated “BBB-” by Kroll Bond Rating Agency*
-
UPDATE: Maxim Group Upgrades Denny's Corporation (DENN) to Buy Following Buyback Announcement
-
Survey Shows Declining Apple (AAPL) iPhone User Retention Rates - Analyst
-
OncoSec Sets the Record Straight on Alpha Holdings’ False and Misleading Statements
-
Maxim Group Downgrades Onconova Therapeutics (ONTX) to Hold
-
Caliber Imaging & Diagnostics, Inc. Secures $5.0 Million in Debt Financing from Bridge Bank concurrent with $1.5 Million Equity Financing
-
Maxim Group Downgrades Adamis Pharmaceuticals (ADMP) to Hold
-
Adamis shares slump as FDA declines to approve opioid overdose treatment
-
Maxim Group Upgrades Applied DNA Sciences (APDN) to Buy
-
Maxim Group Starts Precipio (PRPO) at Buy
-
XAI Octagon Floating Rate & Alternative Income Term Trust Closes Public Offering of Common Shares
-
County Bancorp (ICBK) PT Raised to $26 at Maxim Group
-
Yield10 Bioscience Inc (YTEN) PT Lowered to $0.50 at Maxim Group
-
Applied DNA Sciences Announces Closing of Upsized $12.0 Million Underwritten Public Offering
-
XAI Octagon Floating Rate & Alternative Income Term Trust Prices Public Offering of Common Shares
-
Maxim Group Upgrades SELLAS Life Sciences Group (SLS) to Buy
-
XAI Octagon Floating Rate & Alternative Income Term Trust Commences Public Offering of Common Shares
-
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2019 Financial Results
-
VistaGen Therapeutics (VTGN) PT Lowered to $1 at Maxim Group
-
Maxim Group Downgrades Apple (AAPL) to Sell
-
Nicolet Bankshares (NCBS) PT Raised to $77 at Maxim Group
-
Applied DNA Sciences (APDN) to Offer 2.285M Shares with Warrants at $5.25
-
Applied DNA Sciences Announces Pricing of Upsized $12.0 Million Underwritten Public Offering
-
AmpliTech's Momentum Continues with 3Q 2019 Results
-
Maxim Group Downgrades Craft Brew Alliance (BREW) to Hold
-
Capstone Turbine (CPST) PT Lowered to $3.50 at Maxim Group
-
SCYNEXIS (SCYX) Should Be Up, Now Down on Good Phase 3 Readout - Maxim Group
-
Top Ships (TOPS) Announces Pricing of $8.4 Million Registered Direct Offering of Common Stock, Warrants
-
Top Ships Inc. Announces Pricing of $8.4 Million Registered Direct Offering
-
Two Harbors Investment (TWO) PT Raised to $16 at Maxim Group

